146 related articles for article (PubMed ID: 37019671)
1. [Successful second allogeneic hematopoietic stem cell transplantation with azacitidine as bridging therapy for relapsed juvenile myelomonocytic leukemia].
Oshiro T; Hyakuna N; Abe H; Hamada S; Nakanishi K
Rinsho Ketsueki; 2023; 64(3):187-192. PubMed ID: 37019671
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic Hematopoietic Cell Transplantation for Juvenile Myelomonocytic Leukemia with a Busulfan, Fludarabine, and Melphalan Regimen: JPLSG JMML-11.
Sakashita K; Yoshida N; Muramatsu H; Ohtsuka Y; Watanabe K; Yabe M; Kakuda H; Honda Y; Watanabe T; Haba M; Ohmori S; Matsuda K; Yuza Y; Saito A; Horibe K; Adachi S; Manabe A
Transplant Cell Ther; 2024 Jan; 30(1):105.e1-105.e10. PubMed ID: 37806448
[TBL] [Abstract][Full Text] [Related]
3. A retrospective analysis of azacitidine treatment for juvenile myelomonocytic leukemia.
Honda Y; Muramatsu H; Nanjo Y; Hirabayashi S; Meguro T; Yoshida N; Kakuda H; Ozono S; Wakamatsu M; Moritake H; Yasui M; Sano H; Manabe A; Sakashita K
Int J Hematol; 2022 Feb; 115(2):263-268. PubMed ID: 34714526
[TBL] [Abstract][Full Text] [Related]
4. Molecular assessment of pretransplant chemotherapy in the treatment of juvenile myelomonocytic leukemia.
Hecht A; Meyer J; Chehab FF; White KL; Magruder K; Dvorak CC; Loh ML; Stieglitz E
Pediatr Blood Cancer; 2019 Nov; 66(11):e27948. PubMed ID: 31347788
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis and treatment of juvenile myelomonocytic leukemia in Slovak Republic: novel approaches.
Fabri O; Horakova J; Bodova I; Svec P; Laluhova Striezencova Z; Bubanska E; Cermak M; Galisova V; Skalicka K; Vaska A; Doczyova D; Panikova A; Sykora T; Adamcakova J; Kolenova A
Neoplasma; 2019 Sep; 66(5):818-824. PubMed ID: 31129971
[TBL] [Abstract][Full Text] [Related]
6. Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study.
Dvorak CC; Satwani P; Stieglitz E; Cairo MS; Dang H; Pei Q; Gao Y; Wall D; Mazor T; Olshen AB; Parker JS; Kahwash S; Hirsch B; Raimondi S; Patel N; Skeens M; Cooper T; Mehta PA; Grupp SA; Loh ML
Pediatr Blood Cancer; 2018 Jul; 65(7):e27034. PubMed ID: 29528181
[TBL] [Abstract][Full Text] [Related]
7. Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial.
Niemeyer CM; Flotho C; Lipka DB; Starý J; Rössig C; Baruchel A; Klingebiel T; Micalizzi C; Michel G; Nysom K; Rives S; Schmugge Liner M; Zecca M; Schönung M; Baumann I; Nöllke P; Benettaib B; Biserna N; Poon J; Simcock M; Patturajan M; Menezes D; Gaudy A; van den Heuvel-Eibrink MM; Locatelli F
Blood Adv; 2021 Jul; 5(14):2901-2908. PubMed ID: 34297046
[TBL] [Abstract][Full Text] [Related]
8. DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia.
Flotho C; Sommer S; Lübbert M
Semin Cancer Biol; 2018 Aug; 51():68-79. PubMed ID: 29129488
[TBL] [Abstract][Full Text] [Related]
9. Donor Killer Immunoglobulin Receptor Gene Content and Ligand Matching and Outcomes of Pediatric Patients with Juvenile Myelomonocytic Leukemia Following Unrelated Donor Transplantation.
Rangarajan HG; Pereira MSF; Brazauskas R; St Martin A; Kussman A; Elmas E; Verneris MR; Gadalla SM; Marsh SGE; Paczesny S; Spellman SR; Lee SJ; Lee DA
Transplant Cell Ther; 2021 Nov; 27(11):926.e1-926.e10. PubMed ID: 34407489
[TBL] [Abstract][Full Text] [Related]
10. [Allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia].
Shao Q; Wang ZD; Zheng XL; Dong L; Han DM; Yan HM; Wang HX; Duan LN
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1058-62. PubMed ID: 25130828
[TBL] [Abstract][Full Text] [Related]
11. Azacitidine (Vidaza
Rubio-San-Simón A; van Eijkelenburg NKA; Hoogendijk R; Hasle H; Niemeyer CM; Dworzak MN; Zecca M; Lopez-Yurda M; Janssen JM; Huitema ADR; van den Heuvel-Eibrink MM; Laille EJ; van Tinteren H; Zwaan CM
Paediatr Drugs; 2023 Nov; 25(6):719-728. PubMed ID: 37695474
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.
Voso MT; Leone G; Piciocchi A; Fianchi L; Santarone S; Candoni A; Criscuolo M; Masciulli A; Cerqui E; Molteni A; Finelli C; Parma M; Poloni A; Carella AM; Spina F; Cortelezzi A; Salvi F; Alessandrino EP; Rambaldi A; Sica S
Ann Oncol; 2017 Jul; 28(7):1547-1553. PubMed ID: 28368509
[TBL] [Abstract][Full Text] [Related]
13. Sustained remission with azacitidine monotherapy and an aberrant precursor B-lymphoblast population in juvenile myelomonocytic leukemia.
Hashmi SK; Punia JN; Marcogliese AN; Gaikwad AS; Fisher KE; Roy A; Rao P; Lopez-Terrada DH; Ringrose J; Loh ML; Niemeyer CM; Rau RE
Pediatr Blood Cancer; 2019 Oct; 66(10):e27905. PubMed ID: 31250550
[TBL] [Abstract][Full Text] [Related]
14. Successful hematopoietic stem cell transplantation from an HLA-mismatched parent for engraftment failure after unrelated cord blood transplantation in patients with juvenile myelomonocytic leukemia: Report of two cases.
Akahane K; Watanabe A; Furuichi Y; Somazu S; Oshiro H; Goi K; Sakashita K; Muramatsu H; Hama A; Takahashi Y; Koike K; Kojima S; Sugita K; Inukai T
Pediatr Transplant; 2019 May; 23(3):e13378. PubMed ID: 30786117
[TBL] [Abstract][Full Text] [Related]
15. Haemopoietic cell transplantation in children with juvenile myelomonocytic leukaemia.
MacMillan ML; Davies SM; Orchard PJ; Ramsay NK; Wagner JE
Br J Haematol; 1998 Nov; 103(2):552-8. PubMed ID: 9827934
[TBL] [Abstract][Full Text] [Related]
16. Clinical Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Children with Juvenile Myelomonocytic Leukemia: A Report from the Japan Society for Hematopoietic Cell Transplantation.
Yoshida N; Sakaguchi H; Yabe M; Hasegawa D; Hama A; Hasegawa D; Kato M; Noguchi M; Terui K; Takahashi Y; Cho Y; Sato M; Koh K; Kakuda H; Shimada H; Hashii Y; Sato A; Kato K; Atsuta Y; Watanabe K;
Biol Blood Marrow Transplant; 2020 May; 26(5):902-910. PubMed ID: 31790827
[TBL] [Abstract][Full Text] [Related]
17. Cytosine arabinoside and mitoxantrone followed by second allogeneic transplant for the treatment of children with refractory juvenile myelomonocytic leukemia.
Patel SA; Coulter DW; Grovas AC; Gordon BG; Harper JL; Warkentin PI; Wisecarver JL; Sanger WG; Coccia PF
J Pediatr Hematol Oncol; 2014 Aug; 36(6):491-4. PubMed ID: 24322499
[TBL] [Abstract][Full Text] [Related]
18. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
Gyurkocza B; Gutman J; Nemecek ER; Bar M; Milano F; Ramakrishnan A; Scott B; Fang M; Wood B; Pagel JM; Baumgart J; Delaney C; Maziarz RT; Sandmaier BM; Estey EH; Appelbaum FR; Storer BE; Deeg HJ
Biol Blood Marrow Transplant; 2014 Apr; 20(4):549-55. PubMed ID: 24440648
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study.
Pasvolsky O; Shimony S; Ram R; Shimoni A; Shargian L; Avni B; Wolach O; Shochat T; Yerushalmi R; Amit O; Raanani P; Yeshurun M
Ann Hematol; 2022 Feb; 101(2):379-387. PubMed ID: 34628534
[TBL] [Abstract][Full Text] [Related]
20. BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic leukemia.
Wu Y; Zehnle PMA; Rajak J; Koleci N; Andrieux G; Gallego-Villar L; Aumann K; Boerries M; Niemeyer CM; Flotho C; Bohler S; Erlacher M
Leukemia; 2024 Jan; 38(1):136-148. PubMed ID: 37945692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
